Resultados da busca - Abhinav Deol

Refinar Resultados
  1. 1
    Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

    Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited por Abhinav Deol, Lawrence G. Lum

    Publicado em 2010
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease

    Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease por Divaya Bhutani, Gregory Dyson, Richard Manasa, Abhinav Deol, Voravit Ratanatharathorn, Lois Ayash, Muneer H. Abidi, Lawrence G. Lum, Zaid Al‐Kadhimi, Joseph P. Uberti

    Publicado em 2014
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients

    High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients por Zaid Al‐Kadhimi, Zartash Gul, Wei Chen, Daryn Smith, Muneer H. Abidi, Abhinav Deol, Lois Ayash, Lawrence G. Lum, Edmund K. Waller, Voravit Ratanatharathorn, Joseph P. Uberti

    Publicado em 2014
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

    Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients por Lawrence G. Lum, Archana Thakur, Minsig Choi, Abhinav Deol, Vidya Kondadasula, Dana L. Schalk, Kristie Fields, Melissa Dufrense, Philip Philip, Gregory Dyson, Hussein D. Aon, Anthony F. Shields

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma por Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Muñoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  6. 6
    Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

    Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia por Richard T. Maziarz, Mark J. Levis, Mrinal M. Patnaik, Bart L. Scott, Sanjay Mohan, Abhinav Deol, Scott D. Rowley, Dennis Dong Hwan Kim, Daniela Hernandez, Trivikram Rajkhowa, Kelly Haines, Gaetano Bonifacio, Patrice Rine, Das Purkayastha, Hugo F. Fernández

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

    Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Ax... por Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Javier Muñoz, Tanya Siddiqi, Rhine R. Shen, Adrian Bot, Jinghui Dong, Kanwarjit Singh, Clare Spooner, Roshan Karalliyadda, Jenny J. Kim, Yan Zheng, Sattva S. Neelapu

    Publicado em 2021
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

    Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium por N. Nora Bennani, Matthew J. Maurer, Loretta J. Nastoupil, Michael D. Jain, Julio C. Chávez, Amanda F. Cashen, Saurabh Dahiya, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Frederick L. Locke, Sattva S. Neelapu, Yi Lin

    Publicado em 2019
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel

    Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel por Jay Y. Spiegel, Saurabh Dahiya, Michael D. Jain, John Tamaresis, Loretta J. Nastoupil, Miriam T. Jacobs, Armin Ghobadi, Yi Lin, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, André Goy, Khoan Vu, Charalambos Andreadis, Javier Muñoz, N. Nora Bennani, Julie M. Vose, Kathleen A. Dorritie, Sattva S. Neelapu, Frederick L. Locke, Aaron P. Rapoport, Brian T. Hill, David B. Miklos

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  10. 10
    Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

    Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel) por Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, John M. Rossi, Adrian Bot, Lianqing Zheng, Remus Vezan, Zahid Bashir, Jenny J. Kim, Rong Chu, Sattva S. Neelapu

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids por Olalekan O. Oluwole, Édouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, André Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thiéblemont, John M. Timmerman, Patrick J. Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R. Shen, Harry Miao, Jenny J. Kim, Tom van Meerten

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

    Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Ce... por Michael D. Jain, Miriam T. Jacobs, Loretta J. Nastoupil, Jay Y. Spiegel, Gao Feng, Yi Lin, Matthew A. Lunning, Saurabh Dahiya, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, André Goy, Brian T. Hill, Javier Muñoz, Julio C. Chávez, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, N. Nora Bennani, Charalambos Andreadis, Alison R. Sehgal, Armin Ghobadi, Frederick L. Locke

    Publicado em 2019
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma por Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, André Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thiéblemont, John M. Timmerman, Patrick J. Stiff, Irit Avivi, Dimitrios Tzachanis, Jenny J. Kim, Zahid Bashir, Jeff McLeroy, Yan Zheng, John M. Rossi, Lisa D. Johnson, Lovely Goyal, Tom van Meerten

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

    Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Rela... por Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, A. Keith Stewart, Jordan M. Schecter, Jeffrey L. Goldberg, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Alicia J. Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath

    Publicado em 2021
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

    Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up por Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, A. Keith Stewart, Jordan M. Schecter, Jeffrey L. Goldberg, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Alicia J. Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium por Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier Muñoz, Saurabh Dahiya, Amer Beitinjaneh, Miriam T. Jacobs, Joseph P. McGuirk, Julie M. Vose, André Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros J. Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael Wang, Michael D. Jain

    Publicado em 2023
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

    Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyro... por Erica D. Warlick, Kwang Woo Ahn, Tanya L. Pedersen, Andrew Artz, M. Lima, Michael A. Pulsipher, Görgün Akpek, Mahmoud Aljurf, Jean‐Yves Cahn, Mitchell S. Cairo, Yi‐Bin Chen, Brenda Cooper, Abhinav Deol, Sergio Giralt, Vikas Gupta, H. Jean Khoury, Holbrook E. Kohrt, Hillard M. Lazarus, Ian A. Lewis, Richard F. Olsson, Joseph Pidala, Bipin N. Savani, Matthew D. Seftel, Gèrard Socié, Martin S. Tallman, Celaettin Ustun, Ravi Vij, Lars L. Vindeløv, Daniel J. Weisdorf

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium por Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Jason R. Westin, Julio C. Chávez, Amanda F. Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial por Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jenny J. Kim, William Y. Go, Sattva S. Neelapu

    Publicado em 2018
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) por Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jenny J. Kim, Yan Zheng, Frederick L. Locke

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: